Abstract #1492

A pH-sensitizer can improve cancer immunotherapy treatment as monitored with acidoCEST MRI

Renee L Chin^1,2, Jorge de la Cerda¹, F William Schuler³, Sanhita Sinharay⁴, and Mark D Pagel¹

¹Cancer Systems Imaging, UT MD Anderson Cancer Center, Houston, TX, United States, ²Immunology, MD Anderson Cancer Center, Houston, TX, United States, ³Cancer Systems Imaging, MD Anderson Cancer Center, Houston, TX, United States, ⁴Center for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, India

Synopsis

Keywords: Cancer, CEST & MT, immunotherapyTumor acidosis causes resistance to immune checkpoint blockade (ICB) immunotherapy. We have identified a “pH-sensitizer” that increases the extracellular pH of the tumor microenvironment, improving immunogenicity and tumor control with ICB. AcidoCEST MRI can measure the extracellular pH of the tumor microenvironment. We used acidoCEST MRI to correlate the increase in tumor pHe immediately caused by the pH-senstizer with the tumor volume at study endpoint, in a pre-clinical model of breast cancer. These results show that acidoCEST MRI can contribute to predicting the outcome of immunotherapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.